Merck & Company, Inc. vs Arcus Biosciences, Inc. — Stock Comparison
Merck & Company, Inc. (MRK) and Arcus Biosciences, Inc. (RCUS) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. clearly outscores Arcus Biosciences, Inc. on Q·Score (7 vs 5.1 out of 10), led by Quality (7.7 vs 0.2) and Growth (6.2 vs 4.5). Arcus Biosciences, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for RCUS (+48.2%) than for MRK (+12.4%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 19% return on equity and 14% profit margins.
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-156% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
MRK vs RCUS: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Arcus Biosciences, Inc. (RCUS) at 5.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: MRK or RCUS?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 4.5/10). Merck & Company, Inc. reports revenue growth (4.9% YoY) while Arcus Biosciences, Inc. reports (-39.3% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is MRK or RCUS more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.7/10 vs 6/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about MRK vs RCUS?
There are 27 analysts covering MRK with a consensus price target of $129.74, and 12 analysts covering RCUS with a consensus target of $35.75. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: MRK or RCUS?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 0.2/10). Net profit margin: MRK at 13.6%, RCUS at -156.4%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: MRK or RCUS?
Arcus Biosciences, Inc. (RCUS) scores higher on Financial Health (9.2/10 vs 7/10). Market beta: MRK at 0.22, RCUS at 0.84. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of MRK and RCUS?
Merck & Company, Inc. (MRK) has a market capitalisation of $285.1B, while Arcus Biosciences, Inc. (RCUS) has a market cap of $3.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do MRK or RCUS pay dividends?
MRK pays a dividend yield of 2.95%, while RCUS does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →